Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/PV3B stock hub

FRA/PV3B has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/PV3Bis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

973M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/PV3BFRA/PV3B

—

Loading chart…

In the news

Latest news · FRA/PV3B

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-102.7

P25 n/aP50 n/aP75 n/a

ROIC-1,059.8

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/PV3B market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

155

Groups with data

Currency

USD

Showing 155 of 155 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	214
Employees Change	49%
Employees Change Percent	29.7
Enterprise value	EUR 803M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 973M
Price	EUR 11.2
Price currency	EUR
Rev Per Employee	30,858.05x
Sic	2836
Symbol	fra/PV3B
Website	https://eyepoint.bio

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-24.21%
EV Earnings	-3.41x
EV/Sales	124.13x
P/B ratio	4.87x
P/S ratio	147.35x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	EUR -195M
Net Income	EUR -235.6M
Pretax Margin	-3,564.09%
Profit Per Employee	EUR -1.1M
ROA	-54.13
Roa5y	-24.33
ROCE	-112.4
ROE	-102.7
Roe5y	-57.01
ROIC	-1,059.8

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-7.58%
Cagr15y	-5.65%
Cagr1y	100.45%
Cagr3y	22.45%
Cagr5y	7.37%
Revenue Growth	-86.41x
Revenue Growth Q	-97.15x
Revenue Growth3 Y	-42.38x
Revenue Growth5 Y	-25.98x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.02
Assets	EUR 250M
Cash	EUR 193M
Current Assets	EUR 211.6M
Current Liabilities	EUR 31.8M
Debt	EUR 19.5M
Debt Equity	EUR 0.1
Equity	EUR 199.9M
Interest Coverage	-8,540.1
Liabilities	EUR 50.1M
Long Term Assets	EUR 38.4M
Long Term Liabilities	EUR 18.3M
Net Cash	EUR 173.6M
Net Cash By Market Cap	EUR 17.84
Net Cash Growth	-31.96%
Net Debt Equity	EUR -0.87
Tangible Book Value	EUR 199.9M
Tangible Book Value Per Share	EUR 2.32

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.66
Inventory Turnover	137.6
Net Working Capital	EUR -7.2M
Quick ratio	5.97
Working Capital	EUR 183.9M
Working Capital Turnover	EUR 0.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-27.76%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-54.51%
1Y total return	100.36%
200-day SMA	11.25
3Y total return	83.61%
50-day SMA	11.9
50-day SMA vs 200-day SMA	50over200
5Y total return	42.68%
All Time High	55.54
All Time High Change	-79.83%
All Time High Date	2010-12-22
All Time Low	0.38
All Time Low Change	2,831.94%
All Time Low Date	2020-12-09
ATR	0.38
Ch YTD	-25.97
High	11.2
High52	15.32
High52 Date	2025-12-23
High52ch	-26.89%
Low	11.1
Low52	4.69
Low52 Date	2025-05-15
Low52ch	138.91%
Ma50ch	-5.91%
Price vs 200-day SMA	-0.44%
RSI	46.2
RSI Monthly	51.53
RSI Weekly	48.73
Sharpe ratio	1.19x
Sortino ratio	2.04
Total Return	-27.76%
Tr YTD	-25.97
Tr15y	-58.19%
Tr1m	1.82%
Tr1w	1.82%
Tr3m	4.77%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -244.4M
Operating margin	-3,701.4

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	58,010,736%
Shares Insiders	0.95%
Shares Institutions	71.05%
Shares Qo Q	3.57%
Shares Yo Y	27.76%
Short Ratio	10.7

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	0x
Bv Per Share	2.32
Ch10y	-54.51
Ch15y	-58.19
Ch1m	1.82
Ch1w	1.82
Ch1y	100.4
Ch3m	4.77
Ch3y	83.61
Ch5y	42.68
Ch6m	7.9
Change	1.82%
Change From Open	0.9
Close	11
Days Gap	0.91
Depreciation Amortization	2,025,993.2
Earnings Date	2026-05-06
EBIT	EUR -244.4M
EBITDA	EUR -242.4M
EPS	EUR -3.05
F Score	0
Fiscal Year End	December
Founded	2,000
Income Tax	EUR 198,612
Is Primary Listing	0
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Date	2020-12-09
Last Split Type	Reverse
Ma150	11.84
Ma150ch	-5.37%
Ma20	11.65
Ma20ch	-3.86%
Open	11.1
Position In Range	100
Ppne	16,770,144.5
Price Date	2026-05-08
Ptbv Ratio	4.87
Relative Volume	2,000x
Revenue	6,603,622x
Tax By Revenue	3.01x
Tr6m	7.9%
Volume	0
Z Score	1.37

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/PV3B pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/PV3B stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/PV3B?

Insider, institutional, and short-interest positioning.

Institutional ownership

+71.1%

Share of float held by funds and institutions

Insider ownership

+1.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/PV3B momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.2

Neutral momentum band

Price vs 200-day MA

-0.4%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.19

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/PV3B

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/PV3B stock rating?

fra/PV3B is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/PV3B analysis?

The full report lives at /stocks/fra/PV3B/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/PV3B?

The latest report frames fra/PV3B around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/PV3B page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.